Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Johnson & Johnson 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Johnson & Johnson 1Q Results

Innovative Medicine sales were up 1%, while COVID-19 Vaccine sales were down 97%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
1Q Revenues: $21.4 billion (+2%)
1Q Earnings: $5.4 billion (loss of $491 million 1Q23)
Comments: Innovative Medicine sales were up 1% to $13.6 billion in the quarter. DARZALEX (daratumumab) sales were $2.7 billion, up 19%. ERLEADA (apalutamide) sales were $689 million, up 27%. CARVYKTI (ciltacabtagene autoleucel) sales were $157 million, up from $72 million in 1Q23. TECVAYLI (teclistamab-cqyv) sales were $133 million, up from 63 million in 1Q23. Other Oncology sales were $178 million, up 80% in the quarter. UPTRAVI (selexipag) sales were up 29% to $468 million and OPSUMIT (macitentan) sales were up 19% to $524 million. TREMFYA (guselkumab) sales were up 26% to $808 million. SPRAVATO (esketamine) sales were up 72% to $225 million. COVID-19 Vaccine sales were down 97% to $25 million. XARELTO sales were down 10% to $518 million. REMICADE sales were down 11% to $434 million. ZYTIGA sales were down 26% to $181 million. CONCERTA sales were down 14% to $177 million. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters